Group One Trading’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Group One Trading’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,376	Closed	-$2.31M	–	8389
2023 Q1	$2.22M	Buy	24,376 +4,802	+25%	+$282K	0.01%	1441
2022 Q4	$744K	Buy	+19,574	New	+$674K	﹤0.01%	2683
2022 Q3	–	Sell	-17,725	Closed	-$491K	–	8496
2022 Q2	$539K	Buy	+17,725	New	+$529K	﹤0.01%	3351
2020 Q4	–	Sell	-6,015	Closed	-$790K	–	7168
2020 Q3	$586K	Buy	+6,015	New	+$752K	﹤0.01%	2703
2020 Q2	–	Sell	-146	Closed	-$22.2K	–	6322
2020 Q1	$21K	Sell	146 -1,667	-92%	-$322K	﹤0.01%	4215
2019 Q4	$371K	Buy	1,813 +1,544	+574%	+$282K	﹤0.01%	2676
2019 Q3	$22K	Sell	269 -169	-39%	-$14.3K	﹤0.01%	4326
2019 Q2	$41K	Hold	438	–	–	﹤0.01%	3879
2019 Q1	$37K	Buy	+438	New	+$36.4K	﹤0.01%	3724
2018 Q2	–	Sell	-100	Closed	-$3.05K	–	5588
2018 Q1	$2K	Buy	+100	New	+$2.57K	﹤0.01%	4662

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Group One Trading's RETA Position: Q2 2023 in Review

Group One Trading sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 24,376 shares — an estimated $2.31M sold.

Group One Trading first reported a position in RETA in Q1 2018 and held it in 10 quarters. The position peaked at $2.22M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Group One Trading reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Group One Trading sold 24,376 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $2.31M.
Group One Trading first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 10 quarters.
Group One Trading's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.22M in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.